![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
EDAP TMS SA | NASDAQ:EDAP | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.1384 | 2.78% | 5.1234 | 5.18 | 5.27 | 5.2585 | 5.00 | 5.108 | 28,071 | 19:54:15 |
Marc Oczachowski, EDAP's Chief Executive Officer, commented, "We were pleased with the strong reception that our technology and products received at AUA 2010. This prestigious meeting attracts a broad spectrum of urologists from both the U.S. and around the globe. The four abstracts that were presented represented the largest studies ever conducted among HIFU devices. We are proud of the positive reception that these studies received and expect that awareness will continue to grow globally. These results confirm that this lifestyle preserving treatment for localized prostate cancer is on par with other more invasive treatment options such as surgery."
Based on his strong experience at the largest European Ablatherm-HIFU center, Harlaching Hospital in Munich, Germany, Pr. Christian Chaussy presented an update on HIFU technology for the treatment of localized prostate cancer during a special program dedicated to the Engineering and Urology Society, which promotes the development and application of new technology in urology through the collaborative efforts of engineers, physicists, and urologists. The presentation focused on the engineering community, which is involved in the endorsement and selection of innovative technologies such as HIFU.
Dr. John Rewcastle, EDAP TMS Medical Director, concluded, "These studies, which together report the outcomes of over 1,350 men who have undergone HIFU, underscore the versatility, dependability and success of HIFU as a prostate cancer treatment. Specifically, the large primary and salvage series substantiate earlier observations of HIFU's efficacy but now on a much larger scale. The hormone resistant treatment is novel and may prove to be a valuable treatment for a population of men with limited options."
About EDAP TMS SA
EDAP TMS SA develops and markets Ablatherm, the most advanced and clinically proven choice for high-intensity focused ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. Approved in Europe as a treatment for prostate cancer, Ablatherm-HIFU (High Intensity Focused Ultrasound) is currently undergoing evaluation in a multicenter U.S. Phase II/III clinical trial under an Investigational Device Exemption granted by the FDA, the ENLIGHT U.S. clinical study. The Company also is developing this technology for the potential treatment of certain other types of tumors. EDAP TMS SA also produces and commercializes medical equipment for treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit http://www.edap-tms.com, http://www.hifu-planet.com.
CONTACT: EDAP TMS SA Investor Relations / Legal Affairs Blandine Confort +33 4 72 15 31 72 bconfort@edap-tms.com The Ruth Group Investors: Stephanie Carrington 646-536-7017 scarrington@theruthgroup.com
1 Year EDAP TMS Chart |
1 Month EDAP TMS Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions